HomeENGLISH MAGAZINEFeline shapeshifting: the cat's claw gets "green" fluorine to kill cancer better

Feline shapeshifting: the cat’s claw gets “green” fluorine to kill cancer better

Alkaloids, which are organic compounds produced by plants or microorganisms, have long been used in medicine. One example is morphine, which is extracted from the opium poppy (Papaver somniferum). However, diacetylation of this alkaloid leads to heroin, which is far more potent though it finds no medical application. Narcyssus alkaloids, similarly (Narcyclasines) are enough potent against cancer cells; however, addition of a chlorine atom or a phosphate group enhances their activity several folds higher than the original counterpart. Recent studies have shown that minor modifications in the chemical structure of certain alkaloids can enhance their therapeutic effects. Fluorovinblastine, for example, results from the addition of fluorine to the chemical structure of vinblastine, a natural alkaloid produced by the Rosy periwinkle (Catharanthus roseus). US researchers have demonstrated that the anti-tumor activity of fluorovinblastine is 30 times more potent than that of the natural compound. Researchers in Brazil have prepared modified forms of the alkaloids produced by Uncaria guianensis, a woody vine native to the Amazon Rainforest. Uncaria guianensis is a medicinal plant commonly known as cat’s claw.

The natural versions of alkaloids are widely used to combat tumors and inflammation, and they can help modulate the immune system. The scientists sought to design therapeutically more potent chemicals. The study was supported by São Paulo Research Foundation – FAPESP and conducted by researchers affiliated with the University of Ribeirão Preto (UNAERP) and the Federal University of São Carlos (UFSCar), both in São Paulo State. The results are published in the journal Scientific Reports. The outcome of this small modification was a new alkaloid called 6-fluoro-isomitraphylline, which has three aromatic hydrogens and one fluorine instead of the natural alkaloid’s four aromatic hydrogens. The researchers also produced an analogue called 7-methyl-isomitraphylline by substituting a methyl group for an aromatic hydrogen. Modifications were made to the alkaloids using U. guianensis‘s own metabolic pathways. Plantlets (young plants) not more than 15 cm tall were grown in the laboratory and were fed with water and nutrients. Precursors of the natural alkaloids with small modifications to their structures were added to this liquid medium.

This protocol is called “precursor-directed biosynthesis. The synthesis is done by the plant, to the soil of which is added an analogous key intermediate [precursor], which is captured and inserted into its metabolic route, forming a new alkaloid. Like to pink periwinkle, cat’s claw has an alkaloid metabolism based on the aminoacid tryptophan, which is an advantage. This is ‘green chemistry’, totally free of solvents or reagents, and uses an in vitro plantlet system. The plants were grown for 30 days and then extracted. The extracts were subjected to different types of liquid chromatography and mass spectrometry to identify the substances present in the extract based on their corresponding ions. Following this characterization, chemical processes (chromatography) were used to isolate the alkaloid analogs. The two novel alkaloid analogs modified with fluorine and methyl groups were analyzed by nuclear magnetic resonance (NMR) spectroscopy to confirm their chemical structure. Using this method, approximately one to two milligrams of the new alkaloids were obtained. The next steps will entail increasing the output. The team expects the therapeutic efficacy of the novel compounds obtained from Uncaria guianensis using precursor-directed biosynthesis to be more potent than those produced naturally by the plant.

Adriana Aparecida Lopes, professor in UNAERP’s Biotechnology Unit and first author of the article, explained: “To do so, it will be necessary to silence the production of the natural alkaloids by the plant, as the researchers want the plant to produce only the fluorinated version in their laboratory. We’ll have to silence the enzyme TDC, which is present in the plant’s metabolism and converts the amino acid tryptophan into tryptamine. The plant will cease producing natural tryptamine and will produce only the modified version”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Bamias A et al. Crit Rev Oncol Hematol. 2019; 140:80-87. 

Paeizi M et al. Plant Physiol Biochem. 2018; 132:623-632. 

Keglevich A et al. Molecules. 2018 Oct 9; 23(10).

Sharma A et al. Protoplasma. 2018; 255(5):1281.

Allemann O et al. J Am Chem Soc. 2016; 138(27):8376.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -